Al- though CD4+ T cells generally display minimal in vivo or in vitro lytic activity against tumors, one could say that their activation in the TME determines tumor rejection to a greater extent than activation of CD8+ T cells [52,55]. The gene discussed is CD4; the disease is neoplasm.